Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03214250
What this trial is testing

Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Who this might be right for
Metastatic Pancreatic Adenocarcinoma
Parker Institute for Cancer Immunotherapy 129
Not applicableUnknownNCT03671265
What this trial is testing

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

Who this might be right for
Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07774611
What this trial is testing

An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd. 180
Very early researchUnknownNCT03940001
What this trial is testing

Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer

Who this might be right for
Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital 20
Testing effectiveness (Phase 2)UnknownNCT05982301
What this trial is testing

Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer

Who this might be right for
Gastric CancerChemotherapy EffectImmune Checkpoint Inhibitor
Fudan University 87
Testing effectiveness (Phase 2)Study completedNCT03743766
What this trial is testing

Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Who this might be right for
Melanoma
John Kirkwood 43
Large-scale testing (Phase 3)Looking for participantsNCT03949231
What this trial is testing

Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma

Who this might be right for
Liver Cancer
Second Affiliated Hospital of Guangzhou Medical University 200
Large-scale testing (Phase 3)Looking for participantsNCT06989112
What this trial is testing

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Who this might be right for
Endometrial Cancer
AstraZeneca 600
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06573138
What this trial is testing

Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

Who this might be right for
Lymphoma, Extranodal NK-T-Cell
Ruijin Hospital 18
Early research (Phase 1)Study completedNCT01358721
What this trial is testing

Phase I Biomarker Study (BMS-936558)

Who this might be right for
Renal Cell Carcinoma
Bristol-Myers Squibb 119
Testing effectiveness (Phase 2)Looking for participantsNCT06979908
What this trial is testing

A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
The First Hospital of Jilin University 46
Not applicableLooking for participantsNCT05713994
What this trial is testing

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma Non-resectable
Ze-yang Ding, MD 300
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07243951
What this trial is testing

Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Who this might be right for
Combined Hepatocellular-cholangiocarcinomaLiver Neoplasms
Shanghai Zhongshan Hospital 75
Early research (Phase 1)UnknownNCT03468751
What this trial is testing

Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Henlix, Inc 30
Large-scale testing (Phase 3)WithdrawnNCT04806945
What this trial is testing

A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer

Who this might be right for
Cervical Cancer
Shanghai Henlius Biotech
Testing effectiveness (Phase 2)WithdrawnNCT06361758
What this trial is testing

Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

Who this might be right for
Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Not applicableUnknownNCT05717738
What this trial is testing

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma Non-resectable
Tongji Hospital 300
Testing effectiveness (Phase 2)UnknownNCT03200691
What this trial is testing

Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal NeoplasmsEsophageal Diseases
Hangzhou Cancer Hospital 21
Early research (Phase 1)Study completedNCT03792347
What this trial is testing

Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus

Who this might be right for
Esophageal Squamous Cell Carcinoma
Hecheng Li M.D., Ph.D 20
Early research (Phase 1)Study completedNCT04162327
What this trial is testing

A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor

Who this might be right for
Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd. 55
Next Page